Innovative Molecules, a late-stage clinical biotechnology company focused on the development of differentiated antiviral therapies, has announced the first patient dosed in its phase 2a clinical trial evaluating adibelivir (IM-250) for the treatment of recurrent genital herpes.
The initiation of patient dosing marks a significant value-inflection point for the company and advances its lead programme into proof-of-concept development. The phase 2a study is designed to evaluate the safety, antiviral activity, pharmacokinetics, and clinical efficacy of adibelivir in patients with recurrent genital herpes.
Adibelivir is a novel, orally available helicase-primase inhibitor with a differentiated mechanism of action targeting herpes simplex virus (HSV) replication. The programme has successfully progressed through clinical development and now enters a stage focused on demonstrating therapeutic benefit in patients.
The advancement of adibelivir into phase 2a further strengthens Innovative Molecules’ growing virology franchise. In parallel, the company recently expanded its pipeline through the development of a novel antiviral program targeting Epstein-Barr virus (EBV), one of the most prevalent and clinically significant human viral infections worldwide. The EBV programme is currently progressing through IND-enabling activities.
